Nanoparticle vaccine aiming to cure pancreatic cancer
Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer
A nanoparticle vaccine combined with immune checkpoint blockers aimed at curing people with pancreatic ductal adenocarcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11234277 on NIH RePORTER |
What this research studies
Researchers are designing ionizable lipid nanoparticles that deliver multiple tumor antigens from common pancreatic cancer mutations (for example KRAS and p53) to activate antigen-presenting cells. They plan to combine these nanovaccines with drugs that block immune checkpoints to strengthen the body's anti-tumor immune response. Advanced magnetic resonance molecular imaging will be used to watch, non-invasively, how the vaccines and immune response reach and affect tumors in real time. The team hopes this multi-target approach can overcome tumor heterogeneity and the immunosuppressive tumor microenvironment that limit current therapies.
Who could benefit from this research
Good fit: Ideal candidates would be people with pancreatic ductal adenocarcinoma whose tumors carry the targeted mutant oncogenes (such as KRAS or p53) and who are medically able to receive immunotherapy and serial MRI imaging.
Not a fit: People with other cancer types, tumors lacking the targeted mutations, or those unable to tolerate immunotherapy or MRI scans may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could produce long-lasting disease-free survival or even a cure for some people with pancreatic ductal adenocarcinoma.
How similar studies have performed: Immune checkpoint blockers and some cancer vaccines have worked well in other cancers, but combining targeted nanovaccines with checkpoint inhibitors is largely untested and has not yet produced consistent success in pancreatic cancer.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Lu, Zheng-Rong — Case Western Reserve University
- Study coordinator: Lu, Zheng-Rong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.